Search
Ubiquinol
go.drugbank.com/drugs/DB11340ApprovedInvestigationalnot classified as a vitamin because it is synthesized by humans. … It plays an essential role in maintaining cellular defense against oxidative damage and also sustains the effects of vitamin E by regenerating the vitamin from the tocopheroxyl radical, but ubiquinol is
Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedIt is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
Trefoil Factor 2
go.drugbank.com/drugs/DB15750ExperimentalThe trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells,...
AX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.
Phenindamine
go.drugbank.com/drugs/DB01619ApprovedAntihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold.
SP1049C
go.drugbank.com/drugs/DB04978Experimental[A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.
AP5346
go.drugbank.com/drugs/DB04992InvestigationalIt is being pursued by Access Pharmaceuticals, Inc. … AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
TAK-475
go.drugbank.com/drugs/DB05317InvestigationalTAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigational[L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562] … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).